Event-free survival at 24 months may become an important clinical endpoint in mantle cell lymphoma in the future. A study showed "unexpected" results related to race and MDS survival... The efficacy of enasidenib in patients with AML depends on the mutation type. Blood Cancers Today Associate Editor Elias Jabbour, MD, gave his thoughts on the first day of the 2022 SOHO Annual Meeting. As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies. SOHO President Moshe Talpaz, MD, shares how it feels to be back onsite for the Annual Meeting. The 2022 SOHO Annual Meeting kicked off with remarks from 2022-2023 President Moshe Talpaz, MD. In his President's Letter, Moshe Talpaz, MD, discusses all of the treatment progress made for hematologic malignancies. President-Elect Jennifer R. Brown, MD, PhD, will take office during the 10th Annual SOHO Conference. Dr. Garcia-Manero discusses research from the MDS/AML Moon and what he’s looking forward to as President-Elect of SOHO.